Table 1.

Subject demographics

Healthy
Subject #	Age (yrs)	Sex	BMI	PC20 (mg/ml)	FEV1 (L)	FEV1 (%)
1	24	M	32.9	>25	6.58	113
2	36	M	32.3	>25	3.90	93
3	26	M	31.5	>25	3.50	81
4	31	F	27.7	>25	3.75	104
5	58	M	31.3	>25	3.51	95
6	21	F	31.1	>25	3.92	110
7	50	M	29.6	>25	3.64	103
8	27	M	36.7	>25	5.41	105
9	59	F	28.4	>25	1.81	87
10	22	F	37.8	>25	4.05	117
Avg	35.4	6 M, 4 F	31.9		4.01	100.8
SD	14.8		3.3		1.25	11.6

Asthma
Subject #	Age (yrs)	Sex	BMI	PC20 (mg/ml)	FEV1 (L)	FEV1 (%)	Asthma Medications
1	26	F	35.2	0.25	2.22	73	Fluticasone/salmeterol, Albuterol
2*	19	F	28.6	-	3.39	94*	Fluticasone/salmeterol, Montelukast, Albuterol, cetrizine
3	48	F	36.4	0.747	2.35	82	Fluticasone, Albuterol
4	52	F	41.6	-	1.08	40	Fluticasone, Albuterol
5	56	M	28.1	16	2.36	77	Fluticasone, Albuterol
6	25	F	31.7	0.446	3.37	103	Albuterol
7	19	F	28.8	7.823	3.75	103	Albuterol
8	30	M	26.4	1.536	3.10	80	Fluticasone, Albuterol, Loratadine
9	31	F	46.4	0.683	2.06	62	Albuterol
10	20	F	33.1	1.49	2.83	85	Albuterol, Loratadine
Avg	32.6	2 M, 8 F	33.6	3.6	2.65	79.9
SD	14.1		6.4	5.2	0.79	19.0
P-Value	0.67		0.47		0.01	0.01

^*First and best FEV₁, subject bronchoconstricted with each subsequent FEV₁ maneuver